Infliximab for the treatment of patients with checkpoint inhibitor associated acute tubular interstitial nephritis

Infliximab for the treatment of patients with checkpoint inhibitor associated acute tubular interstitial nephritis

Acute tubular interstitial nephritis (ATIN) is the most frequently reported pathology in patients with checkpoint inhibitor (CPI) induced acute kidney injury (AKI). Glucocorticoid (GC) therapy and discontinuation of CPI are the mainstay of treatment to prevent permanent renal dysfunction and dialysi...

Full description

Bibliographic Details
Main Authors: Jamie S. Lin, Omar Mamlouk, Umut Selamet, Amanda Tchakarov, William F. Glass, Rahul A. Sheth, Rachel M. Layman, Ramona Dadu, Noha Abdel-Wahab, Maen Abdelrahim, Adi Diab, Cassian Yee, Ala Abudayyeh
Format: Article
Language:English
Published: Taylor & Francis Group 2021-01-01
Series:OncoImmunology
Subjects:
checkpoint inhibitors
immune-related adverse event
acute interstitial nephritis
Online Access:http://dx.doi.org/10.1080/2162402X.2021.1877415

Internet

http://dx.doi.org/10.1080/2162402X.2021.1877415

Similar Items